Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Fernandes Moça Trevisani, Virginia ^a   Castro, Aldemar A ^b   Ferreira Neves Neto, João ^a   Atallah, Álvaro N ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b State University of Heath Science   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE; IMMUNOSUPPRESSIVE AGENT; NEUROPROTECTIVE AGENT;

DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ELECTROENCEPHALOGRAPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; MEDICATION COMPLIANCE; MENTAL DISEASE; MORTALITY; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SLEDAI; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; COGNITIVE DEFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CYCLOPHOSPHAMIDE; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHYLPREDNISOLONE; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEIZURES;

EID: 84875534238     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002265.pub3     Document Type: Review

References (42)

1. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al.Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematous. Annals of the Rheumatic Diseases 2005;64:620-5.
2. Austin HA, Klippel JH, Balow JE. Therapy of lupus nephritis. New England Journal of Medicine 1986;314:614-9.
3. Boumpas DT, Austin III HA, Vaughn EM, Klippel JH, Steinberg ASD, Yarboro CH, et al.Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
4. Cortés-Hernández J, Ordi-Ros J, Labrador M, Segarra A, Tovar JL, Balalada E, et al.Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003;12:287-96.
5. Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Annals of Internal Medicine 1982;96(6 Pt 1):728-35.
6. Donatio JV, Holley KE, Ferguson RH, Istrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. New England Journal of Medicine 1978;23:1151-5.
7. Edwards JCW, Snaith ML, Isenberg DA. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment. Annals of the Rheumatic Diseases 1987;46:773-6.
8. Euler HH, Schroeder JO, Zeuner RA, Teske E. A randomised trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: design of the LPSG trial. International Journal of Artificial Organs 1991;14(10):639-46.
9. Fries JF, Sharp GC, McDevitt HO, Holman HR. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis and Rheumatism 1973;16(2):154-62.
10. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al.Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Annals of Internal Medicine 1996;125(7):549-57.
11. Harisdangkul V, Rockhold L, Myers A. Lupus nephritis: efficacy of monthly pulse therapy with intravenous methylprednisolone. Southern Medical Journal 1989;82(3):321-7.
12. Kopelman B. A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus. Lupus 2003;12(12):947-9.
13. Lavalle-Graef A, Villegas-Acosta L, Lavalle C. Trends of anticardiolipin antibodies after low-dose methylprednisolone and cyclophosphamide treatment of systemic lupus erythematosus. Archives of Medical Research 2004;35:421-7.
14. Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Annals of the Rheumatic Diseases 2004;63(3):321-3.
15. Levey AS, Lan S-P, Corwin HL, Kasinath BS, Lachin J, Neilson EG, et al.Progression and remission of renal disease in the lupus nephritis collaborative study. Annals of Internal Medicine 1992;116(2):114-23.
16. Liebling MR, McLaughlin K, Boonsue S, Kasdin J, Barnett EV. Monthly pulses of methylprednisolone in SLE nephritis. Journal of Rheumatology 1982;9:543-8.
17. Mackworth-Young CG, David J, Morgan SH. A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus. Annals of the Rheumatic Diseases 1988;47:496-502.
18. Mok CC, Lau CS, Wong RW. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance; an open-label study. American Journal of Medicine 2003;115:59-62.
19. Neuwelt CM, Lacks S, Kaye BR, Ellamn JB, Borestein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. American Journal of Medicine 1995;98:32-41.
20. Ramos PC, Mendez PRJ, Ames MA, Khamashta, Hughes GRV. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clinical and Experimental Rheumatology 1996;14:295-9.
21. Sesso R, Monteiro M, Sato E, Kiirsztajn G, Silva L, Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994;3:107-12.
22. Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL. Cyclophosphamide in lupus nephritis: a controlled trial. Annals of Internal Medicine 1971;75:165-71.
23. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis & Rheumatism 1991;34(8):945-9.
24. Stojanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 2003;12:3-7.
25. Stratta P, Canavese C, Dogliani M, Thea A, Ferrero S, Tognarelli G, et al.Intravenous cyclophosphamide pulse therapy in the treatment of systemic lupus erythematosus. Contributions to Nephrology 1992;99:126-8.
26. Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Annals of the Rheumatic Diseases 2003;63:525-9.
27. Aranow C, Ginzler EM. Treatment of non-renal lupus. Rheumatology. Vol. 2, Mosby, 2008:1309-18.
28. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al.EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee affairs. Annals of the Rheumatic Diseases 2010;69:2074-82.
29. Bonfa E, Golombek SJ, Kaufman LD. Association between lupus psychosis and anti-ribosomal P protein antibodies. New England Journal of Medicine 1987;317:265-71.
30. Boumpas DT, Austin HA, Fessler BJ, James E, Ballow JE, Klippel JH, et al.Systemic lupus erythematosus; emerging concepts. Annals of Internal Medicine 1995;122:940-50.
31. Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis and Rheumatism 1994;37:1311-9.
32. Denburg JA, Denburg SD, Carbotte RM, Sakic B, Szechtman H. Nervous system lupus: pathogenesis and rationale for therapy. Scandinavian Journal of Rheumatology 1995;12:263-73.
33. Eyanson S, Passo MH, Aldo-Benson MA, Benson MD. Methylprednisolone pulse therapy for nonrenal lupus erythematosus. Annals of the Rheumatic Diseases 1980;39:377-80.
34. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. New England Journal of Medicine 1984;311:1528-33.
35. Gladman DD, Urowitz MB. Clinical features of systemic lupus erythematosus. In: Klippel JH, Dieppe PA editor(s). Rheumatology. Baltimore: Mosby, 1994:(6) 2.1-2.20.
36. Gono T, Kawaguchi Y, Kaneko H, Nishimura K, Hanaoka M, Kataoka S, et al.et al.Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology 2011;50(9):1578-85.
37. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chapter 11: Presenting results and 'Summary of findings' tables.
39. Sibley JT, Olszynski PW, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus is independent of active disease. Journal of Rheumatology 1992;19:47-52.
40. Tan EM, Conhen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism 1982;25:1271-7.
41. Urowitz M, Gladman DD, Abel T. Neuropsychiatric lupus. Journal of Rheumatology 1980;7:326-33.
42. Wolkowitz OM, Reus VI, Weingartter H, Thompson K, Breir A, Doran A, et al.Cognitive effects of corticosteroids. American Journal of Psychiatry 1990;147:1297-303.